Based on the Innate Pharma stock forecast from 0 analysts, the average analyst target price for Innate Pharma is not available over the next 12 months. Innate Pharma’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Innate Pharma is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, Innate Pharma’s stock price was USD 2.90. Innate Pharma’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +2.11% over the last year.
No recent analyst target price found for Innate Pharma
No recent average analyst rating found for Innate Pharma
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and pe...Read More
Frequently Asked Questions About Innate Pharma (IPHYF) Stock
Stock Target Advisor's fundamental analysis for Innate Pharma's stock is Bearish.
Unfortunately we do not have enough data on IPHYF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on IPHYF's stock to indicate what its average analyst target is.
IPHYF stock's Price/Earning ratio is 13.53.
Our analysis grades IPHYF stock's Price / Earning ratio at F. This means that IPHYF stock's Price/Earning ratio is above 50% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this IPHYF may be fairly valued for its sector
The last closing price of IPHYF's stock was USD 2.90.
The most recent market capitalization for IPHYF is USD 0.24B.
Unfortunately we do not have enough analyst data on IPHYF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Innate Pharma's stock.
As per our most recent records Innate Pharma has 168 Employees.
Innate Pharma's registered address is 117, Avenue de Luminy, Marseille, France, 13009.
You can get more information about it from Innate Pharma's website at https://www.innate-pharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Innate Pharma (IPHYF) Stock
Stock Target Advisor's fundamental analysis for Innate Pharma's stock is Bearish.
Unfortunately we do not have enough data on IPHYF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on IPHYF's stock to indicate what its average analyst target is.
IPHYF stock's Price/Earning ratio is 13.53.
Our analysis grades IPHYF stock's Price / Earning ratio at F. This means that IPHYF stock's Price/Earning ratio is above 50% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this IPHYF may be fairly valued for its sector
The last closing price of IPHYF's stock was USD 2.90.
The most recent market capitalization for IPHYF is USD 0.24B.
Unfortunately we do not have enough analyst data on IPHYF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Innate Pharma's stock.
As per our most recent records Innate Pharma has 168 Employees.
Innate Pharma's registered address is 117, Avenue de Luminy, Marseille, France, 13009.
You can get more information about it from Innate Pharma's website at https://www.innate-pharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IPHYF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
